A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

Vaccine Effectiveness and Seroconversion to 23 Valent Pneumococcal Polysaccharide Vaccination in Children With Type 1 Diabetes

The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.

Inclusion Criteria:

• Children ages 3-18 years old.
• Clinical diagnosis of Type 1 diabetes.

Exclusion Criteria:

• Newly diagnosed with Type 1 diabetes with in the past month of study date.
• Contraindications to receiving 23 valent pneumococcal vaccines.
• Other conditions associated with compromised immunity and vaccine response.
• Primary or Secondary Immune deficiency.
• Previous receipt of PPSV-23 vaccination.